Autopsy report · NCT03361137
Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures
Cause of deathSlow enrollment
“The Sponsor decided to terminate the study early for several reasons (low enrollment, limited variety of surgery types, and available scientific data).”
Life of this trial
- Registered 7 months before it started.
- Ran for about 1 year 9 months before it stopped.
- 14 participants enrolled.
- Results were posted on the registry 1 year after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 4
- Sponsor
- Genentech, Inc.
- Sponsor type
- Industry
- Conditions
- Hemophilia A
- Interventions
- Emicizumab
- Participants
- 14
- Sites
- 8
- Countries
- United States
Trials that died the same way
- A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
“Due to low enrollment, the Sponsor decided to prematurely terminate the study” - An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
“The sponsor decided to terminate the study early” - A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
“Sponsor decision to early terminate the study” - Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
“Sponsor decided to terminate the study” - LIONS (PLK4 Inhibitor in Advanced Solid Tumors)
“Sponsor decided to terminate study early”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.